1 / 22

Gregg W. Stone MD for the ACUITY Investigators

Gregg W. Stone MD for the ACUITY Investigators. A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the ACUITY Trial. Disclosures. Gregg W. Stone Consultant to The Medicines Company and BMS Imaging

suki-english
Download Presentation

Gregg W. Stone MD for the ACUITY Investigators

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary SyndromesFinal One-Year Results from the ACUITY Trial

  2. Disclosures Gregg W. Stone Consultant to The Medicines Company and BMS Imaging Honoraria from The Medicines Company and Nycomed

  3. Study Design – First Randomization Medical management UFH/Enox + GP IIb/IIIa (n=4,603) PCI Bivalirudin + GP IIb/IIIa (n=4,604) Angiography within 72h R* Bivalirudin Alone (n=4,612) CABG Moderate and high risk unstable angina or NSTEMI undergoing an invasive strategy (N = 13,819) 33% Moderate and high risk ACS (n=13,819) 56% Aspirin in all Clopidogrel dosing and timing per local practice 11% *Stratified by pre-angiography thienopyridine use or administration

  4. Study Design – Second Randomization UFH/Enox + GP IIb/IIIa (N=4,603) GPI upstream (N=2294) GPI CCL for PCI (N=2309) Bivalirudin + GP IIb/IIIa (N=4,604) GPI upstream (N=2311) R* GPI CCL for PCI (N=2293) Bivalirudin Alone (N=4,612) Moderate and high risk unstable angina or NSTEMI undergoing an invasive strategy (N = 13,819) Moderate and high risk ACS (n=13,819 Aspirin in all Clopidogrel dosing and timing per local practice *Stratified by pre-angiography thienopyridine use or administration

  5. Baseline Characteristics * creatinine clearance <60 mL/min

  6. Baseline High Risk Features *80.1% were biomarker+ or had baseline STΔ †97% were TIMI intermediate or high risk, or biomarker+, or +STΔ

  7. Primary Endpoint Measures (ITT) – 30 Days UFH/Enoxaparin + GPI vs. Bivalirudin + GPI p value(non inferior)(superior) UFH/Enox + IIb/IIIa Primary endpoint Risk ratio ±95% CI Bival + IIb/IIIa RR (95% CI) <0.001 0.93 Net clinical outcome 11.8% 11.7% 1.01 (0.90-1.12) 0.015 0.39 Ischemic composite 7.7% 7.3% 1.07 (0.92-1.23) Upper boundary non-inferiority <0.001 0.38 Major bleeding 5.3% 5.7% 0.93 (0.78-1.10) Bivalirudin + IIb/IIIa better UFH/Enox + IIb/IIIa better Stone GW et al. NEJM 2006;355:2203-16

  8. Primary Endpoint Measures (ITT) – 30 Days UFH/Enoxaparin + GPI vs. Bivalirudin Alone p value(non inferior)(superior) UFH/Enox + IIb/IIIa Primary endpoint Risk ratio ±95% CI Bival alone RR (95% CI) <0.001 0.015 Net clinical outcome 10.1% 11.7% 0.86 (0.77-0.97) 0.01 0.32 Ischemic composite 7.8% 7.3% 1.08 (0.93-1.24) Upper boundary non-inferiority <0.001 <0.001 Major bleeding 3.0% 5.7% 0.53 (0.43-0.65) Bivalirudin alone better UFH/Enox + IIb/IIIa better Stone GW et al. NEJM 2006;355:2203-16

  9. Patient Follow-up at 1-Year* Heparin + IIb/IIIa 4,603 Bivalirudin + IIb/IIIa 4,604 Bivalirudin alone 4,612 All patients N = 13,819 25 Withdrawn 62 Lost to follow-up 25 Withdrawn 66 Lost to follow-up 33 Withdrawn 69 Lost to follow-up Heparin + IIb/IIIa 4,516 (98.1%) 1-year FU Bivalirudin + IIb/IIIa 4,502 (97.8%) 1-year FU Bivalirudin alone 4,521 (98.0%) 1-year FU *Endpoints adjudicated: Composite ischemia (death, MI, unplanned revasc) and stent thrombosis R

  10. Ischemic Composite Endpoint(Death, MI, unplanned revascularization for ischemia) 30 day P (log rank) 1 year P (log rank) Estimate Estimate p=0.55 UFH/Enoxaparin + IIb/IIIa 7.4% — 16.3% — 0.36 0.38 Bivalirudin + IIb/IIIa 7.8% 16.5% 0.34 0.31 Bivalirudin alone 7.9% 16.4% UFH/Enoxaparin + GPI vs. Bivalirudin + GPI vs. Bivalirudin Alone 25 20 15 Ischemic Composite (%) 10 Bivalirudin+GPI vs. Hep+GPI HR [95% CI] = 1.05 (0.94-1.16) 5 Bivalirudin alone vs. Hep+GPI HR [95% CI] = 1.05 (0.95-1.17) 0 0 30 60 90 120 150 180 210 240 270 300 330 360 390 Days from Randomization

  11. Composite Ischemia at 1-Year 17.7% 16.4% 1.14 (0.99-1.30) 14.6% 16.1% 0.95 (0.80-1.14) 16.2% 17.2% 0.97 (0.86-1.11) 16.4% 14.3% 1.20 (1.01-1.44) 19.8% 19.2% 1.09 (0.96-1.23) 21.1% 20.7% 1.04 (0.79-1.36) 9.0% 9.6% 0.97 (0.76-1.24) UFH/Enoxaparin + GPIIb/IIIa vs. Bivalirudin alone 1 yr KM estimate UFH/Enox + IIb/IIIa Hazard ratio ±95% CI Bival alone HR (95% CI) Pint Biomarkers (CK/Trop) Elevated (n=5072) Normal (n=3402) 0.11 Pre Thienopyridine Yes (n=5751) No (n=3305) 0.07 Actual Treatment PCI (n=5179) CABG (n=1040) Medical (n=2994) 0.67 Bivalirudin alone better UFH/Enox + IIb/IIIa better

  12. Myocardial Infarction p=0.24 UFH/Enoxaparin + IIb/IIIa Bivalirudin + IIb/IIIa Bivalirudin alone UFH/Enoxaparin + GPI vs. Bivalirudin + GPI vs. Bivalirudin Alone 15 30 day P (log rank) 1 year P (log rank) Estimate Estimate 4.4% — 6.2% — 4.6% 0.69 6.4% 0.63 10 4.8% 0.36 7.1% 0.10 MI (%) 5 0 0 30 60 90 120 150 180 210 240 270 300 330 360 390 Days from Randomization

  13. Unplanned Revascularization 30 day P (log rank) 1 year P (log rank) Estimate Estimate p=0.39 UFH/Enoxaparin + IIb/IIIa 2.3% — 8.6% — 0.20 0.17 Bivalirudin + IIb/IIIa 2.8% 9.5% 0.72 0.52 Bivalirudin alone 2.4% 8.9% UFH/Enoxaparin + GPI vs. Bivalirudin + GPI vs. Bivalirudin Alone 15 10 Unplanned Revasc. (%) 5 0 0 30 60 90 120 150 180 210 240 270 300 330 360 390 Days from Randomization

  14. Stent Thrombosis (Protocol Defn.) Drug-eluting Stents (DES) vs. Bare Metal Stents (BMS) 5 1 year P (log rank) Estimate All BMS (N=2528) 2.3% 4 0.38 All (N=7158) 2.2% ≥1 DES (N=4630) 2.2% 3 Stent Thrombosis (%) 2 1 0 0 30 60 90 120 150 180 210 240 270 300 330 360 390 Days from Randomization

  15. Stent Thrombosis (Protocol): Definite/Probable P1 = Bivalirudin+GPI vs. UFH/Enox+GPI; P2 = Bivalirudin alone vs. UFH/Enox+GPI

  16. Mortality: 524 total deaths at 1-year p=0.90 UFH/Enoxaparin + IIb/IIIa Bivalirudin + IIb/IIIa Bivalirudin alone P (log rank) 1 year P (log rank) Estimate Estimate 1.4% — 4.4% — 0.53 0.93 1.6% 4.2% 0.39 0.66 1.6% 3.8% UFH/Enoxaparin + GPI vs. Bivalirudin + GPI vs. Bivalirudin Alone 5 Bivalirudin+GPI vs. Hep+GPI HR [95% CI] = 0.99 (0.80-1.22) 4 Bivalirudin alone vs. Hep+GPI HR [95% CI] = 0.95 (0.77-1.18) 3 Mortality (%) 2 30 day 1 0 0 30 60 90 120 150 180 210 240 270 300 330 360 390 Days from Randomization

  17. Death at 1-Year 4.8% 5.0% 1.04 (0.80-1.34) 2.4% 3.6% 0.84 (0.55-1.28) 3.5% 4.2% 0.90 (0.68-1.18) 4.0% 4.4% 1.05 (0.74-1.48) 3.2% 4.0% 0.95 (0.70-1.29) 6.8% 6.7% 1.03 (0.64-1.66) 4.0% 4.3% 0.95 (0.66-1.37) UFH/Enoxaparin + GPIIb/IIIa vs. Bivalirudin alone 1 yr KM estimate UFH/Enox + IIb/IIIa Hazard ratio ±95% CI Bival alone HR (95% CI) Pint Biomarkers (CK/Trop) Elevated (n=5072) Normal (n=3402) 0.40 Pre Thienopyridine Yes (n=5751) No (n=3305) 0.52 Actual Treatment PCI (n=5179) CABG (n=1040) Medical (n=2994) 0.96 Bivalirudin alone better UFH/Enox + IIb/IIIa better

  18. Early and Late MortalityLandmark analysis 30 day P (log rank) Estimate p=0.45 UFH/Enoxaparin + IIb/IIIa 1.4% — Bivalirudin + IIb/IIIa 0.53 1.6% Bivalirudin alone 0.39 1.6% 30d - 1 year P (log rank) Estimate 3.1% — 0.54 2.7% 0.21 2.3% 4 3 Mortality (%) 2 1 0 0 30 60 90 120 150 180 210 240 270 300 330 360 390 Days from Randomization

  19. Major Bleed only (without MI) (N=551) 12.5% MI only (without Major Bleed) (N=611) 8.6% No MI or Major Bleed (N=12,557) Both MI and Major Bleed (N=94) 28.9% 3.4% Impact of MI and Major Bleeding (non-CABG) in the First 30 Days on Risk of Death Over 1 Year 1 yearEstimate 30 28.9% 25 20 Mortality (%) 15 12.5% 10 8.6% 5 3.4% 0 0 30 60 90 120 150 180 210 240 270 300 330 360 390 Days from Randomization

  20. Cox model adjusted for baseline predictors, with non-CABG major bleeding and MI as time-updated covariates Influence of Major Bleeding and MI in the First 30 Days on Risk of Death Over 1 Year HR (95% CI) P-value HR ± 95% CI

  21. Influence of Non-CABG Major Bleeding and MI in the First 30 Days on the Risk of Death Over 1 Year HR ± 95% CI Deaths (n/%) P-value HR (CI) 0.5 1 2 4 8 16

  22. Conclusions • In patients with moderate and high risk ACS undergoing an early invasive strategy with the use of GP IIb/IIIa inhibitors • Bivalirudin is an acceptable substitute for either unfractionated heparin or enoxaparin • Compared to either UFH/enoxaparin with GP IIb/IIIa inhibitors or bivalirudin with GP IIb/IIIa inhibitors • A bivalirudin alone strategy results in marked reduction of bleeding at 30 days, and similar rates of mortality and composite ischemia at 1-year • The results of this study further establish the important relationship between iatrogenic bleeding complications and subsequent mortality in patients with ACS

More Related